On October 7th, Guangxi Wuzhou Zhongheng Group (600252.SH) announced that its holding subsidiary Chongqing Lummy Pharmaceutical Co., Ltd. (referred to as "Lummy Pharmaceutical") recently received the National Medical Products Administration's approved cephalosporin cefoperazone dry suspension (specification: 50mg) "Drug Supplementary Application Approval Notice".
中恒集团(600252.SH)：控股子公司获得药品补充申请批准通知书
Guangxi Wuzhou Zhongheng Group (600252.SH): The holding subsidiary has obtained a pharmaceutical supplementary application approval letter.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated